Board of Directors

The Board of Directors of NeuraMetrix AB

Jan Samzelius

Chairman of the Board of Directors of NeuraMetrix AB since 2021 and Chairman of the Board of Directors of NeuraMetrix, Inc. on and off since 2013

Shareholdings in NeuraMetrix AB (including related persons): xx xxx xxx shares.
Jan Samzelius is co-founder, CEO and CTO of NeuraMetrix, Inc. He has specialized in quantitative methods for 40 years and has invented the typing cadence technology central to NeuraMetrix. Jan has previously led a large number of analytical projects, ranging from measuring customer satisfaction to price elasticities to conjoint analyses. He has been the CEO of six companies (most of them startups), in several cases improving profits dramatically. His experience includes one turnaround and one successful exit.  Jan holds a BSc in Economics from the Stockholm School of Economics (Sweden), graduating with honors and an MBA from Harvard Business School.

Claes Holmberg

Board member of NeuraMetrix AB 

Shareholdings in NeuraMetrix AB (including related persons): x xxx xxx shares.
Claes has been Chairman of the Board of Emotra since October 2018. During the period February 2012 to October 2018, he was a board member and CEO of Emotra. Claes has experience as CEO of, among others, Nobel Pharma AB / Nobel Biocare AB, MediTeam AB / Biolin AB and Biolight AB. He has also been chairman of the board and board member of a number of medical technology companies and in national interdisciplinary research programs. Claes has a Master’s degree in engineering physics and received his PhD in theoretical physics in 1986.

Sir Roy Anderson

Board member of NeuraMetrix AB since 2021 

Shareholdings in NeuraMetrix AB: 0 shares.
Sir Roy is Professor of Infectious Disease Epidemiology in the School of Public Health, Faculty of Medicine, Imperial College London and Director of the Centre for Neglected Tropical Disease Research. His recent appointments include Rector of Imperial College London and Chief Scientist at the Ministry of Defense, UK. Sir Roy’s research interests are in interdisciplinary studies at the interface between medicine, biology, mathematics and computation. He is the author of Over 600 scientific articles and has sat on many government committees and international Bureau committees to provide advice on public health and disease control, including World Health Organization (WHO) and UNAIDS. Among many other merits, Sir Roy was knighted in 2006 by Queen Elizabeth II. Sir Roy holds a BSc and a PhD in Biology and Parasitology with First Class Honors from Imperial College London.
 
Ongoing assignments: Chairman of the Board of Oriole Global Health Ltd and a member of the Advisory Board for Oxford Nanoimaging and the Board of the London Institute of Mathematical Sciences.
 
Independent in relation to both the company and its management as well as to major shareholders

Anders Blom

Board member of NeuraMetrix AB since 2021 

Shareholdings in NeuraMetrix AB: 0 shares.
Anders has more than 25 years of experience within international finance and business development from the pharmaceutical and medical device industries. His experience includes business and corporate development at Pharmacia & Upjohn, and Q-Med AB (publ) (today Galderma); partner and CEO at venture capital firm Nexttobe AB; and Executive VP and CFO at Oasmia Pharmaceutical AB (publ). In addition, Anders has extensive board experience from pharma- and technology sectors including, but not limited to, Hansa Biopharma AB (publ), Biolamina AB, Delta Projects AB, and Selego AB. Anders holds a BSc in Business Administration and Economics from Uppsala University.
 
Ongoing assignments: Chairman of the board of Maida Vale Capital AB, board member of Alzinova AB (publ), Hunterhex International Inc., Hunterhex AB, Wonderboo AB, Rosland Nordic AB and Challengehop Inc. 
 
Independent in relation to the company and its management but not to major shareholders

Ingela Hallberg

Board member of NeuraMetrix AB since 2020

Shareholdings in NeuraMetrix AB: 0 shares.
Ingela is a medical doctor with clinical experience from Sahlgrenska Hospital, Gothenburg. For more than 20 years, Ingela has worked in leading roles in the pharmaceutical industry at several large companies such as Bayer, Lundbeck, Merck KgA, Otsuka and the CRO company Quntiles (today IQVIA), both in clinical research and strategic roles. For just over a year now, Ingela has been working under her own auspices and helping start-ups / smaller companies in the life science area with medical, strategic and clinical development issues.
 
Ongoing assignments: Board member of life science companies Cellink AB since 2017 and MedVasc AB since 2019.
 
Independent in relation to both the company and its management as well as to major shareholders.

Martin Schalling, MD, PhD

Board member of NeuraMetrix AB since 2021

Shareholdings in NeuraMetrix AB: 0 shares.
Martin is Professor of Medical Genetics at the Department of Molecular Medicine and Surgery and the Center for Molecular Medicine at Karolinska Institutet and Karolinska University Hospital. The object of Schalling's research is to identify genetic, epigenetic and environmental factors that are predisposed to the development of neuropsychiatric and metabolic disorders. He is a visiting professor at the University of Sao Paulo, the academic coordinator for KI collaborations with the Mayo Clinic and the University of Minnesota and a member of the editorial board of the Open Psychiatry Journal, Current Psychiatry Reviews and has co-organized a number of world congresses.
 
Ongoing assignments: Chairman of the board of Swedish Mental Health Fund, board member of Suicide Zero, and AMB Industri AB.
 
Independent in relation to both the company and its management as well as to major shareholders.

Julia Viklund

Board member of NeuraMetrix AB since 2021

Shareholdings in NeuraMetrix AB: 0 shares.
Julia is currently a consultant at Ekan Management, where she handles assignments that include organization, development and competence development of finance and controller functions with associated processes and system support. Julia has previous experience of varying financial roles and development projects in various industries. She has mainly worked in a three-part role between finance, HR and SAP support. Julia has a Master's degree in management with a focus on strategy from the Gothenburg School of Economics (Sweden).
 
Ongoing assignments:
 
Independent in relation to both the company and its management but not to major shareholders.